High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity

Liver International : Official Journal of the International Association for the Study of the Liver
S JohanssonJeroen Aerssens

Abstract

Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV)-infected patients has been linked with the IL28B genotype and lower peripheral levels of the CXCR3-binding chemokine IP-10 (CXCL10). To further improve the understanding of these biomarkers we investigated plasma levels of the other CXCR3-binding chemokines and activity of the dipeptidyl peptidase IV (DPP4, CD26) protease, which cleaves IP-10, in relation to treatment response. African-American and Caucasian HCV genotype 1-infected patients (n = 401) were treated with pegIFN/RBV for 48 weeks (ViraHep-C cohort). Pretreatment plasma levels of MIG (CXCL9), I-TAC (CXCL11) and the type III interferon IL29 were investigated by Luminex and DPP4 activity by using a luciferase assay. Patients achieving SVR had higher baseline MIG plasma levels and lower DPP4 activity than non-SVR patients. MIG was higher in Caucasians, IL28B CC (rs1297860) genotype carriers and patients with higher ALT levels. MIG correlated with IP-10 in SVR patients, but not in non-SVRs. A high DPP4 activity correlated with higher IP-10 levels, while DPP4 activity was not associated with MIG or I-TAC levels. The associations of MIG with SVR st...Continue Reading

References

Jun 1, 1995·Journal of Hepatology·K IshakR N MacSween
Aug 10, 2001·Scandinavian Journal of Gastroenterology·G FirneiszUNKNOWN Hungarian Viral Hepatitis Study Group
Nov 6, 2002·The Journal of Biological Chemistry·Ian Clark-LewisPius Loetscher
May 3, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·T AndrieuA Cahour
May 4, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Karla J HelbigMichael R Beard
Aug 8, 2006·Gastroenterology·Hari S ConjeevaramUNKNOWN Virahep-C Study Group
Sep 29, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert J FontanaUNKNOWN Virahep-C Study Group
Jan 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Manoj ThapaDaniel J J Carr
Sep 18, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marija ZeremskiAndrew H Talal
Dec 17, 2008·World Journal of Gastroenterology : WJG·Juan R LarrubiaTrinidad Parra-Cid
Sep 15, 2009·Nature Genetics·Vijayaprakash SuppiahJacob George
Oct 24, 2009·The Journal of Infectious Diseases·Marija ZeremskiAndrew H Talal
Feb 27, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Galia AskariehUNKNOWN DITTO-HCV and NORDynamIC Study Groups
Oct 12, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Thomas J UrbanNezam Afdhal
Dec 15, 2010·Journal of Hepatology·Bettina LanghansUlrich Spengler
Dec 25, 2010·The Journal of Clinical Investigation·Armanda CasrougeMatthew L Albert
Jan 12, 2011·Immunology and Cell Biology·Joanna R Groom, Andrew D Luster
Jan 22, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jama M DarlingMichael W Fried
Mar 30, 2011·Alimentary Pharmacology & Therapeutics·G FattovichUNKNOWN ITAHEC Study Group
Apr 23, 2013·Acta Virologica·K LopušnáP Kabát
Jan 29, 2014·Clinical Pharmacology : Advances and Applications·Astrid WendtMarc Bourlière

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.